Rabeprazole clinical trials
Rabeprazole is named as an intervention in 5 current clinical trials in our China, USA, South Korea and Taiwan registers. 4 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Genentech, Inc (1). The most-studied condition is Healthy Volunteers.
Where Rabeprazole is approved
All regulators →Of the three regulators tracked here, the first to approve Rabeprazole was the US, on 19 Aug 1999. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Rabeprazole
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Rabeprazole works
All drug targets →- Potassium-transporting ATPase inhibitor InhibitorTarget: Potassium-transporting ATPaseChEMBL only
- Helicobacter pylori infectious diseasePhase 3
- AsthmaPhase 3
- Duodenal ulcerPhase 3
- Peptic esophagitisPhase 3
- Laryngopharyngeal RefluxPhase 2/3
- DyspepsiaPhase 2
- Myocardial infarctionPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1219, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7290, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Rabeprazole
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Rabeprazole.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia NICE TA7 | Recommended | 23 Jul 2000 | Replaced |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Rabeprazole
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 6 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Rabeprazole
- ATC code
- A02BC04
- ChEMBL
- CHEMBL1219
- DrugBank
- DB01129
- PubChem CID
- 5029
- CAS number
- 117976-89-3
- FDA UNII
- 32828355LL
- Wikidata
- Q3515
- Wikipedia
- Rabeprazole
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Rabeprazole
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Rabeprazole across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
6 single-substance products containing Rabeprazole on the HPRA medicines list.
- PARIET 20 mg gastro-resistant tabletJanssen Sciences Ireland Unlimited Company · PA22612/009/002 · Marketed
- Rabeprazole Krka 10mg Gastro-Resistant TabletsKRKA, d.d., Novo mesto · PA1347/030/001 · Marketed
- Rabeprazole Krka 20mg Gastro-Resistant TabletsKRKA, d.d., Novo mesto · PA1347/030/002 · Marketed
- PARIET 10 mg gastro-resistant tabletJanssen Sciences Ireland Unlimited Company · PA22612/009/001 · Not marketed
- Razole 10 mg Gastro-resistant tabletsRowa Pharmaceuticals Limited · PA0074/073/001 · Not marketed
Supply shortages
No entry for Rabeprazole in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Rabeprazole
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Genentech, Inc | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Dizal Pharmaceuticals | 1 |
| Yonsei University | 1 |
| Chih-An Shih, MD | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in South Korea | 1 | 1 |
| Clinical trials in Taiwan | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Rabeprazole trials
How many clinical trials are testing Rabeprazole?
5 current trials in our China, USA, South Korea and Taiwan registers name Rabeprazole as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Rabeprazole trials recruiting patients?
Yes. 4 of the 5 trials are recruiting: 2 with sites in China, 1 with sites in USA and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rabeprazole clinical trials?
Genentech, Inc (1), Second Affiliated Hospital, Zhejiang University, School of Medicine (1), Dizal Pharmaceuticals (1) and Yonsei University (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Rabeprazole licensed in Ireland?
Yes. The HPRA medicines list includes 6 single-substance products containing Rabeprazole, for example PARIET 20 mg gastro-resistant tablet (Janssen Sciences Ireland Unlimited Company). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Rabeprazole shortage?
Not in the lists we track: Rabeprazole has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rabeprazole works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rabeprazole works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rabeprazole (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.